These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3306213)

  • 41. The pathogenesis of hypertension in obese subjects.
    Weidmann P; de Courten M; Boehlen L; Shaw S
    Drugs; 1993; 46 Suppl 2():197-208; discussion 208-9. PubMed ID: 7512475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease.
    Esler M; Kaye D
    J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S1-7. PubMed ID: 11346214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and haemodynamic effects of ketanserin in lean and obese hypertensive patients.
    Licata G; Scaglione R; Parrinello G; Capuana G; Mazzola G; Lipari R; Castello R; Galantino L
    J Int Med Res; 1990; 18(2):112-9. PubMed ID: 2340944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Left ventricular hypertrophy in hypertensive obese women.
    Paunović K; Jakovljević B; Stojanov V
    Acta Cardiol; 2006 Dec; 61(6):623-9. PubMed ID: 17205919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiac function in massively obese patients and the effect of weight loss.
    Herrera MF; Deitel M
    Can J Surg; 1991 Oct; 34(5):431-4. PubMed ID: 1913384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor.
    Messerli FH; Ketelhut R
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S7-13. PubMed ID: 7507540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The heart in obesity-hypertension.
    Morse SA; Bravo PE; Morse MC; Reisin E
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):647-58. PubMed ID: 16076275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical and hemodynamic effects of medium-term ketanserin treatment in 2 compared groups of obese and non-obese hypertensive patients].
    Licata G; Scaglione R; Parrinello G; Capuana G; Mazzola G; Lipari R; Galantino L; Castello R
    G Clin Med; 1989 Oct; 70(10):597-603. PubMed ID: 2599284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Obesity-hypertension: the effects on cardiovascular and renal systems.
    Zhang R; Reisin E
    Am J Hypertens; 2000 Dec; 13(12):1308-14. PubMed ID: 11130776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Right heart function during prosthetic left ventricular assistance in a porcine model of congestive heart failure.
    Chow E; Farrar DJ
    J Thorac Cardiovasc Surg; 1992 Sep; 104(3):569-78. PubMed ID: 1513147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The combined effect of systemic hypertension and obesity on biventricular diastolic function.
    Myśliński W; Mosiewicz J; Dzida G; Hanzlik J
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):431-6. PubMed ID: 12898875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical determinants and consequences of left ventricular hypertrophy.
    Messerli FH
    Am J Med; 1983 Sep; 75(3A):51-6. PubMed ID: 6226196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium and obesity in the pathogenesis of hypertension.
    Reisin E
    Am J Hypertens; 1990 Feb; 3(2):164-7. PubMed ID: 2155002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance.
    Haber HL; Simek CL; Bergin JD; Sadun A; Gimple LW; Powers ER; Feldman MD
    J Am Coll Cardiol; 1993 Jul; 22(1):251-7. PubMed ID: 8509548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertension in obese subjects: distinct hypertensive subgroup.
    Licata G; Scaglione R; Capuana G; Parrinello G; Di Vincenzo D; Mazzola G
    J Hum Hypertens; 1990 Feb; 4(1):37-41. PubMed ID: 2345385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiology of anaemia: focus on the heart and blood vessels.
    Metivier F; Marchais SJ; Guerin AP; Pannier B; London GM
    Nephrol Dial Transplant; 2000; 15 Suppl 3():14-8. PubMed ID: 11032352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obesity and target organ damage: the heart.
    Schunkert H
    Int J Obes Relat Metab Disord; 2002 Dec; 26 Suppl 4():S15-20. PubMed ID: 12457294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathophysiology of hypertension: effects of calcium antagonists on heart and kidney.
    Frohlich ED
    J Cardiovasc Pharmacol; 1989; 13 Suppl 1():S11-7. PubMed ID: 2468971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific features of left ventricular hypertrophy in hypertensive obese women. An echocardiographic study.
    Lusiani L; Ronsisvalle G; Ambrosio GB; Nicolin P; Baggio B; Inelmen EM; Enzi G; Visonà A; Scaladalai E; Pagnan A
    Int J Obes; 1989; 13(6):809-16. PubMed ID: 2533585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output.
    Messerli FH; Ventura HO; Reisin E; Dreslinski GR; Dunn FG; MacPhee AA; Frohlich ED
    Circulation; 1982 Jul; 66(1):55-60. PubMed ID: 7083520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.